Thanks to the EPI-PHARE system, reinforced surveillance of vaccines against the coronavirus is set up by various health experts. They assessed the dangers of cardiovascular events in people aged 75 and over using a study combining two specialties, pharmacology and epidemiology.

One of the previous French studies had already shown that the Comirnaty vaccine from the Pfizer / BioNtech laboratory was 87% effective against severe forms of Covid-19. However, some health professionals, vaccinated people or their entourage have reported via the pharmacovigilance system in France, “ potential cardiovascular event signals [who] have been identified for the Comirnaty vaccine “. Following these statements, a large study was therefore necessary to quantify the risks of cardiovascular events linked to the vaccine from Pfizer. This large study involved patients aged 75 and over who were admitted to hospital between December 15, 2020 and March 20, 2021 for a cardiovascular event. These people were vaccinated against Covid-19.

The results are rather encouraging, because within two weeks of vaccination with Pfizer serum, whether after the first or the second dose, the risk of a cardiovascular event ” does not differ significantly […] of the risk during the control periods of the same people “. Indeed, according to the results, published by the National Medicines Safety Agency (ANSM), “ there is no increased risk of serious cardiovascular events Such as myocardial infarction, cerebrovascular accident (stroke), ischemic stroke or pulmonary embolism in people in this age group. It is now time to analyze the results in other populations and other age groups, especially in younger people and those with a history of cardiovascular events.